EICHOR
● Enrolling By Invitation
Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
Condition: Idiopathic Pulmonary Fibrosis · Interstitial Lung Disease · Progressive Pulmonary Fibrosis · Sponsor: United Therapeutics
About this study
Study RIN-PF-302 is designed to evaluate the long-term safety and tolerability of inhaled treprostinil in subjects with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (192)
| The University of Alabama at Birmingham | Birmingham, Alabama, United States | — |
| Clinical Trials Center of Middle Tennessee | Franklin, Arizona, United States | — |
| Banner University Medical Center-Phoenix | Phoenix, Arizona, United States | — |
| St. Joseph's Hospital and Medical Center - Norton Thoracic Institute | Phoenix, Arizona, United States | — |
| University of Arizona | Tucson, Arizona, United States | — |
| UC San Diego Health | La Jolla, California, United States | — |
| David Geffen School of Medicine at UCLA | Los Angeles, California, United States | — |
| NewportNativeMD, Inc | Newport Beach, California, United States | — |
| Palmtree Clinical Research, Inc. | Palm Springs, California, United States | — |
| UC Davis Health Medical Center | Sacramento, California, United States | — |
| University of California San Francisco | San Francisco, California, United States | — |
| Stanford University School of Medicine | Stanford, California, United States | — |
+ 180 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04905693